These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32067841)

  • 21. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A specific assay for anti-HLA antibodies: application to platelet donor selection.
    Millard FE; Tani P; McMillan R
    Blood; 1987 Nov; 70(5):1495-9. PubMed ID: 3311206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet transfusion refractoriness and anti-HLA immunization.
    Blandin L; Dougé A; Fayard A; Bay JO; Berlie G; Pereira B; Lemal R; Rouzaire P
    Transfusion; 2021 Jun; 61(6):1700-1704. PubMed ID: 33709433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches.
    Pandey S; Rosenbaum E; Cottler-Fox M; Harville TO
    Ann Clin Lab Sci; 2017 May; 47(3):315-318. PubMed ID: 28667033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-CD36 Mediated Platelet Transfusion Refractoriness and Related Cases After Stem Cell Transplantation].
    Zhou Y; Li LL; Zhong ZL; Liu XJ; Liu JL; Shen WD; Wu GG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):541-546. PubMed ID: 29665929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory response to platelet transfusion therapy.
    Eisenberg S
    J Infus Nurs; 2010; 33(2):89-97. PubMed ID: 20228646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet crossmatching. A direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient.
    Kickler TS; Ness PM; Braine HG
    Am J Clin Pathol; 1988 Jul; 90(1):69-72. PubMed ID: 3389345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
    Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity.
    Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM
    Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B
    Front Immunol; 2023; 14():1125367. PubMed ID: 36845153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet crossmatch tests using radiolabelled staphylococcal protein A or peroxidase anti-peroxidase in alloimmunized patients.
    Yam P; Petz LD; Scott EP; Santos S
    Br J Haematol; 1984 Jun; 57(2):337-47. PubMed ID: 6375714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C; Barroso J; Gernsheimer T; Metcalf RA; Warner P; Pagano MB
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience.
    Karlström C; Linjama T; Edgren G; Lauronen J; Wikman A; Höglund P
    Transfusion; 2019 Mar; 59(3):945-952. PubMed ID: 30575964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
    Wiita AP; Nambiar A
    Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors.
    Vox Sang; 2003 Jan; 84(1):73-88. PubMed ID: 12542737
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibodies to private and public HLA class I epitopes in platelet recipients.
    Zimmermann R; Wittmann G; Zingsem J; Blasczyk R; Weisbach V; Eckstein R
    Transfusion; 1999 Jul; 39(7):772-80. PubMed ID: 10413287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.